In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole
about
Fluconazole pharmacokinetics and safety in premature infantsFluconazole dosing for the prevention or treatment of invasive candidiasis in young infantsPopulation pharmacokinetics of fluconazole in young infants.First dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole.Clinical and microbiological characteristics, and impact of therapeutic strategies on the outcomes of children with candidemia.Abdominal candidiasis is a hidden reservoir of echinocandin resistance.Fluconazole loading dose pharmacokinetics and safety in infantsFluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation.Association of fluconazole pharmacodynamics with mortality in patients with candidemiaBreakthrough candidemia in children: clinical and microbiological characteristics, therapeutic strategies and impact on outcomes.Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit.Prevention of invasive Candida infections in preterm infants: the time is now.Breakthrough candidemia after the introduction of broad spectrum antifungal agents: A 5-year retrospective study.Risk assessment for extending the Biopharmaceutics Classification System-based biowaiver of immediate release dosage forms of fluconazole in adults to the paediatric population.Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized open-label clinical trial.
P2860
Q27014816-BE02A661-F6E8-4FA1-B30F-3601F7EBF3B1Q30435365-211318A4-E836-46A4-B42A-C0C77ABC69C2Q30439710-7248BD00-60AD-4B0A-B045-3D500E564416Q30844731-45AC1246-3A23-4AE0-BD78-BB88D91CEC22Q33683476-7B2AE2EC-B544-42C0-A6B9-46EB4BBA0815Q34597421-D5AD8D8E-AAD6-4491-9178-365C94570DACQ34807770-7C42479E-53A8-4FDE-A4BE-866C8EB22AA0Q35746253-59F24DE8-B774-46A9-B677-7389C2765312Q36870712-CB589DEF-60D0-4659-A898-080679A660E8Q38741813-957170FB-7E3F-4019-BEAA-0C080FD092B9Q43737173-40DD20FD-41AF-45A9-A290-7964EE3DDC7DQ46459098-C9E83121-9820-4DEB-A01F-1D5110E1363FQ50113587-629E527B-57B2-4582-8676-0BEF03869B65Q50593909-967A7CDC-EB02-4C31-9043-FA5818DCFF9EQ53823442-13918324-F72D-4A1E-ABFE-E7FB9413EE01
P2860
In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
In vitro susceptibility of bre ...... umulative doses of fluconazole
@en
type
label
In vitro susceptibility of bre ...... umulative doses of fluconazole
@en
prefLabel
In vitro susceptibility of bre ...... umulative doses of fluconazole
@en
P2093
P2860
P356
P1476
In vitro susceptibility of bre ...... umulative doses of fluconazole
@en
P2093
Benjamin Staley
Cornelius J Clancy
M Hong Nguyen
P2860
P304
P356
10.1128/AAC.00741-06
P407
P577
2006-10-01T00:00:00Z